[°Ç°­]

¹Ì±¹ CDC¿¡¼­ Á¦°øÇÏ´Â Äڷγª19 ¹é½Å¿¡ ´ëÇÑ Á¤º¸

rank °í¾à 2021-03-07 (ÀÏ) 10:38 Á¶È¸ : 1534 Ãßõ : 9  

¹°·Ð, ¹Ì±¹ CDC°¡ Çѱ¹ Á¶Á÷Àº ¾Æ´Ï°í, Çѱ¹ Áúº´°ü¸®Ã»º¸´Ù CDC°¡ ´õ ³´´Ù°í ¸»ÇÒ ¼öµµ ¾øÁö¸¸, ¹Ì±¹ÀÌ Çѱ¹º¸´Ù ¸ÕÀú Á¢Á¾À» ½ÃÀÛÇß°í, Á¢Á¾ ÄÉÀ̽ºµµ ´õ ¸¹±â ¶§¹®¿¡ Âü°í°¡ µÉ °Í °°½À´Ï´Ù. ´Ù¸¸, ¹Ì±¹ÀÇ °æ¿ì ¾á¼¾ ¹é½ÅÀÌ ½ÂÀÎÀ» ¹Þ¾Ò°í, Çѱ¹Àº ¾Æ½ºÆ®¶óÁ¦³×Ä« ¹é½ÅÀÌ ½ÂÀÎÀ» ¹Þ¾Ò½À´Ï´Ù. ±×·¯³ª ÀÌ µÎ ¹é½ÅÀº ¸ðµÎ ¾Æµ¥³ë¹ÙÀÌ·¯½º º¤ÅÍ ¹é½ÅÀ̱⠶§¹®¿¡ ¾á¼¾¿¡ ¾Æ½ºÆ®¶óÁ¦³×Ä«¸¦ ºñÃ纸½Ã¸é µÉ °Í °°½À´Ï´Ù.

¸¸¾à, ¿©±â ³»¿ë°ú Çѱ¹ Áúº´°ü¸®Ã»ÀÇ Á¤º¸°¡ ¼­·Î »óÃæÇÑ´Ù¸é, Çѱ¹ Áúº´°ü¸®Ã»ÀÇ Á¤º¸¸¦ ¿ì¼±À¸·Î ¿©±â½Ã¸é ÁÁ°Ú½À´Ï´Ù. ³ª¶ó¸¶´Ù »óȲÀÌ ´Ù¸£´Ï±î¿ä.

¿ì¼±, ¿ø¹®Àº ¾Æ·¡ ¸µÅ©¿¡¼­ º¸½Ç ¼ö ÀÖ½À´Ï´Ù. ³»¿ëÀÌ ±æ¾î¼­ ÃÖ´ëÇÑ ÇÊ¿äÇÑ ºÎºÐ¸¸ °£·«ÇÏ°Ô Ã߷ȽÀ´Ï´Ù. ÀÚ¼¼ÇÑ ³»¿ëÀº °ü·Ã ºÎºÐÀ» Á÷Á¢ º¸½Ã¸é ´õ ¸¹Àº Á¤º¸¸¦ º¸½Ç ¼ö ÀÖ½À´Ï´Ù.

https://www.cdc.gov/vaccines/covid-19/info-by-product/clinical-considerations.html

³»¿ë ÆľÇÀÌ ½¬¿ì½Ãµµ·Ï À½½¿Ã¼·Î ½è½À´Ï´Ù. ¾çÇØ ºÎŹµå¸³´Ï´Ù.

Ȥ½Ã Á¦°¡ ¿µ¾î°¡ ª¾Æ¼­ ¹ø¿ªÀÌ À߸øµÈ ºÎºÐÀÌ ÀÖÀ¸¸é, ´ñ±Û·Î ÁöÀûÇØÁÖ½Ã¸é ¹Ù·Î ¼öÁ¤Çϵµ·Ï ÇÏ°Ú½À´Ï´Ù.


[¹é½Å Çã°¡ ¿¬·É]
È­ÀÌÀú ¹é½Å: 16¼¼ ÀÌ»ó
¸ð´õ³ª ¹é½Å: 18¼¼ ÀÌ»ó
¾á¼¾ ¹é½Å: 18¼¼ ÀÌ»ó

[¹é½ÅÁ¢Á¾¹æ¹ý]
È­ÀÌÀú ¹é½Å : 30 ug / 0.3 ml 3ÁÖ°£°Ý 2ȸ
¸ð´õ³ª ¹é½Å : 100 ug / 0.5 ml 4ÁÖ °£°Ý 2ȸ
¾á¼¾ ¹é½Å : 5 X 10 10 ¹ÙÀÌ·¯½º ÆÄƼŬ / 0.5 ml 1ȸ

[¹é½Å Á¢Á¾ °£°Ý¿¡ °üÇÏ¿©]
Á¤ÇØÁø 2Â÷ Á¢Á¾ÀϺ¸´Ù 4ÀÏ Àü±îÁö À̸¥ ³¯Â¥¿¡ Á¢Á¾Çصµ À¯È¿, ºÒ°¡ÇÇÇÏ°Ô 2Â÷ Á¢Á¾ÀÌ ´Ê¾îÁø´Ù¸é, ÃÖ°í 6ÁÖ °£°Ý±îÁö µÎ°í 2Â÷ Á¢Á¾ÇÏ¿©µµ À¯È¿.
However, second doses administered within a grace period of 4 days earlier than the recommended date for the second dose are still considered valid. If it is not feasible to adhere to the recommended interval and a delay in vaccination is unavoidable, the second dose of Pfizer-BioNTech and Moderna COVID-19 vaccines may be administered up to 6 weeks (42 days) after the first dose.

[¹é½ÅÀÇ ±³Â÷Á¢Á¾¿¡ ´ëÇØ]
Çã¿ëÇÏÁö ¾ÊÀ½.
COVID-19 vaccines are not interchangeable.
´Ù¸¸, Ưº°ÇÑ °æ¿ì·Î mRNA¹é½ÅÀ» ¸ÂÀº ÈÄ 2Â÷ Á¢Á¾ÀÌ ºÒ°¡´ÉÇÒ °æ¿ì ¾á¼¾ ¹é½ÅÀ» 4ÁÖ ÈÄ¿¡ Á¢Á¾ÇÒ ¼ö ÀÖ´Ù. ÀÌ·² °æ¿ì ¾á¼¾ ¹é½ÅÀ» Á¢Á¾ÇÑ °ÍÀ¸·Î °£ÁÖÇÑ´Ù.
However, in limited, exceptional situations where a patient received the first dose of an mRNA COVID-19 vaccine but is unable to complete the series with either the same or different mRNA COVID-19 vaccine (e.g., due to contraindication), a single dose of Janssen COVID-19 vaccine may be considered at a minimum interval of 28 days from the mRNA COVID-19 vaccine dose. ..... Patients who receive Janssen COVID-19 vaccine after a dose of an mRNA COVID-19 vaccine should be considered to have received a valid, single-dose Janssen vaccination—not a mixed vaccination series.

[´Ù¸¥ Áúȯ¿¡ ´ëÇÑ ¹é½Å°ú µ¿½Ã¿¡ Á¢Á¾]
´Ù¸¥ Áúȯ¿¡ ´ëÇÑ ¹é½Å(¿¹¸¦µé¸é, ÆÄ»ódz ¹é½Å °°Àº °Å)°ú µ¿½Ã¿¡ Á¢Á¾ÇØ¾ß ÇÑ´Ù¸é Àû¾îµµ 14ÀÏ °£°ÝÀ» µÖ¾ß ÇÑ´Ù. ÇÇÄ¡ ¸øÇÒ »çÁ¤À¸·Î 14ÀÏ ÀÌ»ó °£°ÝÀ» µÎÁö ¸øÇÏ°í µÎ Á¾·ùÀÇ ´Ù¸¥ ¹é½ÅÀ» Á¢Á¾ÇØ¾ß ÇÑ´Ù°í Çصµ, Äڷγª19 ¹é½ÅÀ» Ãß°¡·Î ¶Ç Á¢Á¾ÇÒ ÇÊ¿ä´Â ¾ø´Ù. (È¿°ú´Â Á» ¶³¾îÁú ¼ö ÀÖÁö¸¸ ¾î¿ ¼ö ¾ø´Ù´Â ÀǹÌ)

[Äڷγª19¿¡ °¨¿°µÇ¾ú´ø »ç¶÷Àº?]
ÀÌÀü °¨¿° ¿©ºÎ¿Í »ó°ü¾øÀÌ ¹é½Å Á¢Á¾À» ¹Þ¾Æ¾ß ÇÔ. ¹é½Å Á¢Á¾ Àü¿¡ °¨¿° ÀÌ·Â Å×½ºÆ®µµ ºÒÇÊ¿äÇÔ. (±×³É ¸ðµÎ ´Ù Á¢Á¾Ç϶ó´Â ÀǹÌ)
People should be offered vaccination regardless of history of prior symptomatic or asymptomatic SARS-CoV-2 infection.
Äڷγª19 ȸº¹ ÈÄ ÃÖ¼Ò ¾ó¸¶°¡ Áö³ª¼­ ¹é½ÅÀ» Á¢Á¾ÇØ¾ß ÇÏ´ÂÁöµµ »ó°ü¾øÀ½. (Àç°¨¿°À» ¸·±â À§Çؼ­´Â °¡±ÞÀû »¡¸® ¸Â´Â °ÍÀÌ ÁÁ´Ù°í ¾ð±Þ)
While there is no recommended minimum interval between infection and vaccination

[Äڷγª19¿¡ °¨¿°µÇ¾î Ç×üġ·áÁ¦¸¦ ½è´ø »ç¶÷Àº?]
Ç×üÀÇ ¹Ý°¨±â¸¦ °í·ÁÇϸé, Àû¾îµµ 90ÀÏ ÀÌ»ó Áö³­ ÈÄ¿¡ ¹é½ÅÀ» Á¢Á¾ÇØ¾ß ÇÔ.
Based on the estimated half-life of such therapies and evidence suggesting that reinfection is uncommon in the 90 days after initial infection, vaccination should be deferred for at least 90 days.
¸¸¾à, 1Â÷ Á¢Á¾À» ÇÑ ÈÄ¿¡ °¨¿°µÇ¾î Ç×üġ·áÁ¦¸¦ »ç¿ëÇßÀ» °æ¿ìµµ, Ç×üġ·áÁ¦¸¦ »ç¿ëÇÑ ÀÌÈÄ 90ÀÏÀÌ Áö³ª¼­ 2Â÷ Á¢Á¾À» ÇØ¾ß ÇÔ.
¸¸¾à, Äڷγª19 Ç×üġ·áÁ¦°¡ ¾Æ´Ñ ´Ù¸¥ Áúȯ Ä¡·á ¸ñÀûÀÇ Ç×ü(IVIG, RhoGAM)¸¦ »ç¿ëÇßÀ» °æ¿ì´Â ÀÌ·± Á¦ÇÑ ¾øÀÌ ¹é½ÅÀ» Á¢Á¾ÇÒ ¼ö ÀÖ´Ù.
For people receiving antibody therapies not specific to COVID-19 treatment (e.g., intravenous immunoglobulin, RhoGAM), administration of COVID-19 vaccines either simultaneously with or at any interval before or after receipt of an antibody-containing product is unlikely to substantially impair development of a protective antibody response. Thus, there is no recommended minimum interval between antibody therapies not specific to COVID-19 treatment and COVID-19 vaccination.

[¹é½Å Á¢Á¾ ÈÄ¿¡ Äڷγª19¿¡ °É¸° »ç¶÷]
±âÁ¸ÀÇ Äڷγª19 Ä¡·á¹æ¹ýÀ» ±×´ë·Î Àû¿ëÇÑ´Ù. ¸¸¾à Ç® ¸é¿ªµÈ »ç¶÷ÀÌ Äڷγª19¿¡ È®ÁøµÈ´Ù¸é, »ùÇÃÀ» È®º¸ÇÏ°í VAERS¿¡ º¸°íÇÒ °Í.

[¾Æ³«Çʶô½Ã½º °æÇèÀÚ]
¹é½Å Á¢Á¾À» ±ÇÇÏÁö ¾ÊÀ½.

[È®ÁøÀÚ¿Í ¹ÐÁ¢ Á¢ÃËÀÚ]
ÀÚ°¡ °Ý¸® ±â°£¿¡´Â ¹é½Å Á¢Á¾À» ÇÏÁö ¾Ê´Â´Ù.(È®»êÀÇ ¿ì·Á°¡ ÀÖÀ¸¹Ç·Î) 2Â÷ Á¢Á¾ Àü¿¡ È®ÁøÀÚ¿Í Á¢ÃËÇÏ¿´À» °æ¿ìµµ 2Â÷ Á¢Á¾À» ¹Ì·ï¾ß ÇÑ´Ù.

[¸é¿ªºÎÀüȯÀÚ]
HIV ȯÀÚ³ª ¸é¿ª¾ïÁ¦Á¦¸¦ ¾²´Â »ç¶÷ÀÇ °æ¿ì, µ¥ÀÌÅÍ°¡ ÃæºÐÇÏÁö ¾ÊÀ¸³ª ¹é½ÅÀ» ¾ÈÀüÇÏ°Ô Á¢Á¾ÇÒ ¼ö ÀÖ´Ù.
However, the currently authorized COVID-19 vaccines are not live vaccines and therefore can be safely administered to immunocompromised people.
¸é¿ª ¾ïÁ¦ Ä¡·á¸¦ ÇØ¾ß ÇÏ´Â °æ¿ì´Â, ¹é½Å Á¢Á¾À» ¿ÏÀüÈ÷ ³¡³½ ÈÄ 2ÁÖ ÀÌÈÄ¿¡ ÇØ¾ß ÇÑ´Ù.
¸¸¾à ¸é¿ª ¾ïÁ¦ Ä¡·á ½ÃÀÛ 2ÁÖ Àü¿¡ Äڷγª19 ¹é½Å Á¢Á¾À» ¸¶Ä¥ ¼ö ¾ø´Â °æ¿ì¶óµµ, ¹é½ÅÀ» Á¢Á¾ÇÒ ¼ö ÀÖ´Ù.
However, based on general best practices for vaccination of immunocompromised people, ideally COVID-19 vaccination should be completed at least two weeks before initiation of immunosuppressive therapies. When it is not possible to administer a complete COVID-19 vaccine series in advance, people on immunosuppressive therapy can still receive COVID-19 vaccination.
Ç׾Ͽä¹ýÀ̳ª ¸é¿ª¾ïÁ¦Á¦¸¦ ¾²´Â µµÁß¿¡ ¹é½ÅÀ» Á¢Á¾ÇÑ °æ¿ì, Ä¡·á°¡ ³¡³ª°í ¸é¿ªÀÌ È¸º¹µÈ ÈÄ¿¡ ¹é½ÅÀ» Àç Á¢Á¾À» ÇÒ ÇÊ¿ä´Â ¾ø´Ù.

[¹é½Å Á¢Á¾ ÈÄ Ç×ü °Ë»ç]
±ÇÇÏÁö ¾ÊÀ½. (±×·¯³ª Àڱ⠵·À¸·Î °Ë»çÇÏ·Á¸é ÇÒ ¼ö´Â ÀÖ½À´Ï´Ù.)

[ÀÚ°¡¸é¿ªÁúȯÀÚ]
¹é½ÅÀÇ È¿°ú³ª ¾ÈÀü¼º¿¡ ´ëÇÑ µ¥ÀÌÅÍ´Â ¾øÀ¸³ª, ¹é½ÅÀÇ ÀÓ»óÅ×½ºÆ®¿¡ ÀÌ·± ȯÀÚµéÀÌ Æ÷ÇԵǾú°í, ¾î¶°ÇÑ ¹®Á¦Á¡µµ ¾ø¾ú´Ù. ¹é½Å Á¢Á¾À» ¹ÞÀ» ¼ö ÀÖ´Ù.
No imbalances were observed in the occurrence of symptoms consistent with autoimmune conditions or inflammatory disorders in clinical trial participants who received COVID-19 vaccine compared to placebo. People with autoimmune conditions may receive any authorized COVID-19 vaccine.

[±æ·À-¹Ù·¹ ÁõÈıº ÀÌ·Â]
¹é½ÅÀÇ ÀÓ»óÅ×½ºÆ®¿¡¼­ ±æ·À-¹Ù·¹ ÁõÈıºÀÌ º¸°íµÇÁö ¾Ê¾ÒÀ½. ´Ù¸¸, ¾á¼¾ ¹é½Å ÀÓ»óÅ×½ºÆ®¿¡¼­´Â ¹é½Å ±×·ì¿¡¼­ ÇÑ ¸í, Çöó½Ãº¸ ±×·ì¿¡¼­µµ ÇÑ ¸íÀÌ ¹ß»ýÇÏ¿´À½. µû¶ó¼­, ±æ·À-¹Ù·¹ ÁõÈıº ÀÌ·ÂÀÌ ÀÖ´Â »ç¶÷µµ ¹é½ÅÀ» Á¢Á¾ÇÒ ¼ö ÀÖÀ½. ¸¸¾à ¹é½Å Á¢Á¾ ÈÄ ±æ·À-¹Ù·¹ ÁõÈıºÀÌ ³ªÅ¸³ª¸é, VAERS¿¡ º¸°íÇØ¾ß ÇÔ.
People with a history of GBS may receive COVID-19 vaccination.

[¾È¸é½Å°æ¸¶ºñ, ±¸¾È¿Í»ç ÀÌ·Â]
ÀÓ»óÅ×½ºÆ® Áß¿¡ ¾È¸é½Å°æ¸¶ºñ°¡ º¸°íµÇ¾úÀ¸³ª, FDA´Â ÀÚ¿¬ ¹ß»ý ¹üÀ§¸¦ ÃÊ°úÇÏÁö ¾Ê¾Ò´Ù°í ÆÇ´Ü. µû¶ó¼­ ¹é½Å Á¢Á¾À» ¹ÞÀ» ¼ö ÀÖ´Ù. ¸¸¾à ¹é½Å Á¢Á¾ ÈÄ ¾È¸é½Å°æ¸¶ºñ°¡ ³ªÅ¸³¯ °æ¿ì VAERS¿¡ º¸°íÇØ¾ß ÇÔ.
In the absence of such evidence, people with a history of Bell¡¯s palsy can receive a COVID-19 vaccine.

[ÇÊ·¯ (filler) ¼ºÇü¼ö¼úÀ» ÇÑ »ç¶÷]
ÇǺΠ¾Æ·¡¿¡ ÇÊ·¯¸¦ ³ÖÀº »ç¶÷ÀÌ mRNA¹é½ÅÀ» Á¢Á¾ ¹ÞÀ¸¸é, ÇÊ·¯¸¦ ÁÖÀÔÇÑ °÷°ú ÁÖº¯ºÎ°¡ º×´Â Çö»óÀÌ ³ªÅ¸³². ÀÌ´Â ÀϽÃÀûÀÎ Çö»óÀ̸ç, ½ºÅ×·ÎÀ̵带 »ç¿ëÇϸé ÇØ°áµÊ. ÁÖÄ¡ÀÇ¿Í »ó´ãÇÏ°í ¹é½ÅÀ» Á¢Á¾ÇÒ ¼ö ÀÖÀ½.

[ÀӽźÎ]
°üÂûµÈ µ¥ÀÌÅÍ¿¡ ÀÇÇϸé, Àӽźΰ¡ Äڷγª19¿¡ °É¸®¸é, ÁßÁõÁúȯÀ¸·Î ÀüÀÌµÉ À§Ç輺ÀÌ ´õ ³ôÀ½.
Àӽźο¡ ´ëÇÑ µ¥ÀÌÅÍ°¡ ÃæºÐÇÏÁö ¾ÊÀ¸³ª, È­ÀÌÀú, ¸ð´õ³ª, ¾á¼¾Àº µ¿¹° ½ÇÇèÀ» ÅëÇØ Æ¯º°ÇÑ ¹®Á¦°¡ ¾øÀ½À» Áõ¸íÇÑ ¹Ù ÀÖ´Ù. ´Ù¸¸, ¾á¼¾ÀÇ °æ¿ì À̹ø Äڷγª19 ¹é½Å°ú ÀÌÀüÀÇ ¿¡º¼¶ó ¹é½ÅÀÇ ÀÓ»óÅ×½ºÆ®¿¡ Àӽźθ¦ Æ÷ÇÔ½ÃÄ×°í, ¾Æµ¥³ë¹ÙÀÌ·¯½º º¤ÅÍ ¹é½ÅÀÌ ¹®Á¦¸¦ ÀÏÀ¸Å°Áö ¾ÊÀ½À» º¸¿´´Ù. (Äڷγª19 ¹é½ÅÀÇ °æ¿ì, ¹é½Å ±×·ì 4¸í, Çöó½Ãº¸ ±×·ì 4¸íÀ» Æ÷ÇÔ½ÃÄ×½À´Ï´Ù. ¸Å¿ì ÀûÀº ¼ýÀÚ¿´½À´Ï´Ù.)
ÇöÀç±îÁöÀÇ Á¤º¸¸¦ Á¾ÇÕÇØ º¼¶§, Àü¹®°¡µéÀÇ °ßÇØ´Â ¹é½ÅÀÌ ÀӽźεéÀÇ À§ÇèÀ» Áõ°¡½ÃÅ°Áö ¾Ê´Â´Ù°í ¹Ï°í ÀÖÀ½.
Based on current knowledge, experts believe that COVID-19 vaccines are unlikely to pose a risk to the pregnant person or fetus because the currently authorized COVID-19 vaccines are non-replicating vaccines and cannot cause infection in either the mother or the fetus.
Àӽźδ ¹é½ÅÀ» Á¢Á¾ÇÒ ¼ö ÀÖÀ¸¸ç, ÀÇ·áÁø°ú »ó´ãÀ» ÅëÇØ °áÁ¤¿¡ µµ¿òÀ» ¾òÀ» ¼ö ÀÖÀ¸³ª, ÀÌ·± »ó´ãÀ» ¹Þ¾Æ¾ß ¸¸ÀÌ ¹é½Å Á¢Á¾À» ¹ÞÀ» ¼ö ÀÖ´Â °ÍÀº ¾Æ´Ï´Ù. (ÀÇ·áÁø°ú »ó´ãÇÑ ±â·ÏÀÌ ÀÖ¾î¾ß ¹é½ÅÀ» ¸ÂÀ» ¼ö ÀÖ´Ù´Â Àǹ̰¡ ¾Æ´Ï´Ù¶ó´Â ¶æÀÔ´Ï´Ù.)
Pregnant people may choose to receive a COVID-19 vaccine. A conversation between the patient and their clinical team may assist with decisions about the use of a COVID-19 vaccine, though a conversation with a healthcare provider is not required before vaccination.
ÀӽŠÁß¿¡ ¹é½Å Á¢Á¾À» °áÁ¤ÇÑ »ç¶÷Àº, v-safe¿¡ °¡ÀÔÇÏ¿© ºÐ¸¸ ¶§±îÁö Ãß°¡ÀûÀÎ °ü¸®¸¦ ¹ÞÀ» ¼ö ÀÖÀ½.
¹é½Å Á¢Á¾ ÈÄ¿¡ ¹ß¿­ÀÌ ³ªÅ¸³¯ °æ¿ì ŸÀÌ·¹³îÀ» º¹¿ëÇÒ ¼ö ÀÖÀ½.
°¡Àӱ⠿©¼ºÀÇ °æ¿ì ¹é½Å Á¢Á¾ Àü¿¡ ÀӽŠÁø´Ü Å×½ºÆ®¸¦ º°µµ·Î ÇÒ ÇÊ¿ä´Â ¾øÀ½.
There is no recommendation for routine pregnancy testing before receipt of a COVID-19 vaccine.

[¸ðÀ¯ ¼öÀ¯]
Äڷγª19 ¹é½ÅÀÌ ¸ðÀ¯ ¼öÀ¯¿¡ ¿µÇâÀ» ¹ÌÄ£´Ù´Â Áõ°Å°¡ ¾øÀ½. »ý¹é½ÅÀÌ ¾Æ´Ñ °æ¿ì ¸ðÀ¯ ¼öÀ¯¿¡ À§Ç輺Àº ¾ø´Ù°í ¾Ë·ÁÁ® ÀÖÀ½. µû¶ó¼­ ¸ðÀ¯ ¼öÀ¯ ÁßÀÎ ¿©¼ºµµ ¹é½ÅÀ» ¸ÂÀ» ¼ö ÀÖÀ½.
There are no data on the safety of COVID-19 vaccines in lactating people or the effects of COVID-19 vaccines on the breastfed infant or milk production or excretion. Because non-live vaccines pose no risk for lactating people or their infants, COVID-19 vaccines are also not thought to be a risk. Therefore, lactating people may choose to be vaccinated.

[û¼Ò³â, ¾Æµ¿ÀÇ ¹é½Å Á¢Á¾]
16-17¼¼ÀÇ Ã»¼Ò³âÀº È­ÀÌÀú ¹é½ÅÀ» ¸ÂÀ» ¼ö ÀÖÀ½. ¸ð´õ³ª¿Í ¾á¼¾ ¹é½ÅÀº 18¼¼ ÀÌÇÏ´Â Á¢Á¾ÇÒ ¼ö ¾øÀ½.

[¹é½Å Á¢Á¾ ÈÄ]
ÀÇÇÐÀû ¹®Á¦°¡ ¾ø´Ù¸é, ¹é½Å Á¢Á¾ ÈÄ ºÎÀÛ¿ëÀÌ ³ªÅ¸³¯ °æ¿ì ÇØ¿­ ÁøÅëÁ¦(¾Æ¼¼Æ®¾Æ¹Ì³ëÆæ, NSAID)¸¦ º¹¿ëÇÒ ¼ö ÀÖ´Ù. ±×·¯³ª, ÀÌ·± ºÎÀÛ¿ëÀ» ¹æÁöÇϱâ À§ÇØ »çÀü¿¡ ÀÌ·± ¾àÀ» ¹Ì¸® º¹¿ëÇÏ´Â °ÍÀº, ¹é½Å¿¡ ¾î¶² ¿µÇâÀ» ¹ÌÄ¡´ÂÁö ¾ÆÁ÷ ¸ð¸£±â ¶§¹®¿¡ ±ÇÀåÇÏÁö ¾Ê´Â´Ù.
For all currently authorized COVID-19 vaccines, antipyretic or analgesic medications (e.g., acetaminophen, non-steroidal anti-inflammatory drugs) can be taken for the treatment of post-vaccination local or systemic symptoms, if medically appropriate. However, routine prophylactic administration of these medications for the purpose of preventing post-vaccination symptoms is not currently recommended, because information on the impact of such use on COVID-19 vaccine-induced antibody responses is not yet available.

[Ç×È÷½ºÅ¸¹ÎÁ¦ º¹¿ë]

¾Æ³«Çʶô½Ã½º ¹ßÇöÀ» ¸·±â À§ÇØ, ¹é½Å Á¢Á¾ Àü¿¡ Ç×È÷½ºÅ¸¹ÎÁ¦¸¦ »çÀü¿¡ º¹¿ëÇÏ´Â °ÍÀº ±ÇÀåµÇÁö ¾Ê´Â´Ù. Ç×È÷½ºÅ¸¹ÎÁ¦´Â ¾Æ³«Çʶô½Ã½º¸¦ ¸·¾ÆÁÙ ¼ö ¾øÀ¸¸ç, ¿ÀÈ÷·Á Ç×È÷½ºÅ¸¹ÎÁ¦°¡ ¾Æ³«Çʶô½Ã½º°¡ ³ªÅ¸³ª±â Àü¿¡ º¸¿©Áö´Â ÀüÁ¶ Áõ»óµéÀ» °¡·Á¼­ Áø´ÜÀÌ ´Ê¾îÁú ¼ö ÀÖ´Ù.

´ñ±Û 0°³
´ñ±Û¾²±â

¹øÈ£ Á¦¸ñ ±Û¾´ÀÌ ³¯Â¥ ¡èÃßõ ¡èÁ¶È¸
[·»Å»»ó´ã½Ç]  ¿¬¼ö±â ·»Å» »ó´ã¿ä À͸í
929 [°Ç°­]  ÀþÀº ³ëÀεéÀÇ »ýÈ°½À°ü.youtube  rank¿ë¿Õ 06-23 15 10755
928 [°Ç°­]  Àü¸³¼±¿¡ ´ëÇØ ¾Ë¾ÆµÎÀÚ !  (1) À̹ÌÁö rank»î°úÁ×À½ÀÇ°æ°è 06-22 19 11303
927 [°Ç°­]  ¿ø¼þÀ̵Îâ °ü·Ã Á¤ÀçÈÆ ¿¹¹æÀÇÇаú ±³¼ö ±Û  À̹ÌÁö rankPzGren 06-22 18 11554
926 [°Ç°­]  Á¶Çöº´, 'ÀÌ·± Áõ»ó' ³ªÅ¸³ª¸é ÀǽÉÇØ¾ß ,,,  (2) À̹ÌÁö rankyohji 06-21 14 10769
925 [°Ç°­]  Á¦·ÎÀ½·á, ¸ÅÀÏ ¸¶¼Åµµ ±¦ÂúÀ»±î?.jpg  (2) À̹ÌÁö rank±æ´ë 06-21 15 10623
924 [°Ç°­]  ´ëÀå³»½Ã°æ °Ë»ç  (3) À̹ÌÁö rank»î°úÁ×À½ÀÇ°æ°è 06-20 19 12140
923 [°Ç°­]  ¹Ì¸® ¿©¸§¸ÂÀÌ ´ÙÀ̾îÆ®, À¯»ê¼Ò ¿îµ¿ Æí  À̹ÌÁö rankPzGren 06-20 16 4195
922 [°Ç°­]  ³ëÈ­ÀÇ ¿øÀÎ.jpg  (5) À̹ÌÁö rankÄ¡¿Í¿Õ 06-20 18 5968
921 [°Ç°­]  ±â°üÁö¿°¿¡ Çطοî À½½Ä  À̹ÌÁö rank»î°úÁ×À½ÀÇ°æ°è 06-19 17 1446
920 [°Ç°­]  µ¿ÀǺ¸°¨ »ýÈ° °Ç°­¹ý  À̹ÌÁö rank¥Æ¥Î¥Í¥É¥Ã¥Ç 06-19 15 824
919 [°Ç°­]  Æó¾ÏÀÇ ÃʱâÁõ»ó ¹× °ü·ÃÁ¤º¸  À̹ÌÁö rank»î°úÁ×À½ÀÇ°æ°è 06-18 14 1036
918 [°Ç°­]  ½ÇÁ¦ È¿°úº» 12½Ã°£ ½Ã°£Á¦ÇÑ ´ÙÀ̾îÆ®.jpg  À̹ÌÁö rank¿À¡¾î½É¸® 06-18 17 2190
917 [°Ç°­]  È¸º¹·ÂÀ» ¿Ã·ÁÁÖ´Â À½½Ä  À̹ÌÁö rank¥Æ¥Î¥Í¥É¥Ã¥Ç 06-18 18 1500
916 [°Ç°­]  ³ú¿¡ °¡Àå Ãæ°ÝÀ» ÁÖ´Â ÇൿÀº?  À̹ÌÁö rankPzGren 06-17 14 1266
915 [°Ç°­]  »óº´¼ö´ç ½Åû Á¶°Ç ¹× ½Åû ¹æ¹ý »óº´¼ö´ç±Ý ±Ý¾×  rankÅ©·ë 06-16 13 791
914 [°Ç°­]  ÇÏ·ç¿¡ ¿µ¾çÁ¦ ¸î°³³ª µå¼¼¿ä?  À̹ÌÁö rank¥Æ¥Î¥Í¥É¥Ã¥Ç 06-16 14 1031
913 [°Ç°­]  °í°üÀý ÅëÁõ Ä¡·á ¹× ¿¹¹æ¹ý  À̹ÌÁö rank»î°úÁ×À½ÀÇ°æ°è 06-15 17 859
912 [°Ç°­]  ¿©¼ºÀÌ ¹è¶õ±â¸¦ °¨Ãá ÁøÂ¥ ¼Ó³»´Â?  À̹ÌÁö rankPzGren 06-15 13 1304
911 [°Ç°­]  °í°üÀý ÅëÁõ Áõ»ó  À̹ÌÁö rank»î°úÁ×À½ÀÇ°æ°è 06-14 16 1734
910 [°Ç°­]  ¿ù¿äº´ ±Øº¹ °£´ÜÇÑ ½ºÆ®·¹Äª ¾Ë·ÁÁÖ´Â °­»ç´©³ª.gif  (1) À̹ÌÁö rankÁ¤¸»¾ø½À´Ï´Ù 06-14 20 4258
909 [°Ç°­]  ÀúÇ÷´ç ¼îÅ© ÀÀ±Þ óġ ´ëó¹ý  À̹ÌÁö rank»î°úÁ×À½ÀÇ°æ°è 06-13 17 1855
908 [°Ç°­]  °£´ÜÇÑ ¼ú ÇÑÀÜ, ¸ö¿¡ ÀÌ·Î¿ï ¼öµµ ÀÖÁö ¾ÊÀ»±î?  (2) À̹ÌÁö rankPzGren 06-13 19 3037
907 [°Ç°­]  ¹Ì¸®¾Ë°í, ¿¹¹æÇÏÀÚ! ¿©¸§Ã¶ ½ÄÁßµ¶  À̹ÌÁö rank¹®¼öº¸»ì 06-13 13 858
906 [°Ç°­]  ¾î¸± Àû À½½Ä ½À°ü¡¦Æò»ý °£´Ù  (9) À̹ÌÁö rankPzGren 06-12 23 3979
905 [°Ç°­]  Á¦·ÎÀ½·á´Â °ú¿¬ ¸ö¿¡ Çطο? - Á¦·ÎÀ½·áÀÇ Çã¿Í ½Ç  (2) rankÆÄÁö¿Ã¸® 06-12 14 1325
904 [°Ç°­]  ¾Ï Á¤º¹ÀÌ ¸ÖÁö ¾Ê¾Ò´Ù  (7) À̹ÌÁö rankÏÖí­ÜÃâÂä¨Ò´Ú±Ø¹ 06-12 17 2669
903 [°Ç°­]  ¾Ï¼¼Æ÷¸¦ ¿ÏÀüÈ÷ ¼Ò¸ê½ÃŲ »ç·Ê°¡ º¸°íµÇ¾ú´Ù  rankÆÄÁö¿Ã¸® 06-11 15 1203
902 [°Ç°­]  ¿ø¼þÀ̵Îâ¿¡ °üÇÑ Á¤º¸  À̹ÌÁö rank¥Æ¥Î¥Í¥É¥Ã¥Ç 06-11 14 846
901 [°Ç°­]  ¿Ã¹Ù¸¥ Ä©¼ÖÁú  rank»î°úÁ×À½ÀÇ°æ°è 06-10 15 962
900 [°Ç°­]  ¼ÕÀ» ÀâÀ¸¸é »ý±â´Â ÀÏµé  (9) À̹ÌÁö rank¥Æ¥Î¥Í¥É¥Ã¥Ç 06-10 27 7769
899 [°Ç°­]  ÀÕ¸ö °Ç°­Áö¼ö üũ ¹æ¹ý  (5) À̹ÌÁö rank»î°úÁ×À½ÀÇ°æ°è 06-09 20 3859
898 [°Ç°­]  ¼ú²ÛµéÀÌ ¹Ýµå½Ã ì°Ü¸Ô¾î¾ß ÇÒ ºñŸ¹Î  (2) À̹ÌÁö rankÆÄÁö¿Ã¸® 06-09 14 1286
897 [°Ç°­]  ¿ÏÀü ä½ÄÀº ¾î¸°À̵鿡°Ô ¾ÈÀüÇÒ±î?  (1) À̹ÌÁö rankPzGren 06-09 15 676
896 [°Ç°­]  ¿Ö ä½ÄÁÖÀÇÀÚ´Â ºñŸ¹ÎA °áÇÌÁõÀÌ ¹ß»ýÇÒ±î?  rank±¤²¿ 06-08 16 1162
895 [°Ç°­]  ³ú°æ»ö °ü·Ã Á¤º¸  À̹ÌÁö rank»î°úÁ×À½ÀÇ°æ°è 06-08 14 824
894 [°Ç°­]  °¨Á¤Àû»óó¿¡ ¸Â¼­´Â »ý°¢¹ý  À̹ÌÁö rank¥Æ¥Î¥Í¥É¥Ã¥Ç 06-08 13 1090
893 [°Ç°­]  ³ì³»Àå ¿¹¹æ ¹× Ä¡·á ¹æ¹ý  À̹ÌÁö rank»î°úÁ×À½ÀÇ°æ°è 06-07 14 730
892 [°Ç°­]  ³²ÀÚ ³²±Ù¿¡ ÁÁÀº Ç®¹ß±â¿µ¾çÁ¦ 7¼±.jpeg  (26) À̹ÌÁö rank¿À¡¾î½É¸® 06-07 32 10337
891 [°Ç°­]  ³ì³»Àå ÃʱâÁõ»ó °ü·Ã Á¤º¸  À̹ÌÁö rank»î°úÁ×À½ÀÇ°æ°è 06-06 15 868
890 [°Ç°­]  °ñ¹Ý Ʋ¾îÁü Å×½ºÆ®  (1) À̹ÌÁö rank¥Æ¥Î¥Í¥É¥Ã¥Ç 06-06 15 1453
889 [°Ç°­]  ÈĽõò vs ¸¶µ¥Ä«¼Ö °°Àº ÁÙ ¾Ë¾Ò´Âµ¥ ´Ù¸£´Ù°í?  (1) À̹ÌÁö rankfourplay 06-06 14 1133
888 [°Ç°­]  °©»ó¼±¾Ï °ü·Ã Á¤º¸  À̹ÌÁö rank»î°úÁ×À½ÀÇ°æ°è 06-05 17 1467
887 [°Ç°­]  ÀÕ¸öº´, º×°í ¾ÆÇö§ óġ ¹æ¹ý  (2) À̹ÌÁö rank»î°úÁ×À½ÀÇ°æ°è 06-04 18 1734
886 [°Ç°­]  ¹Ù´Ù, °­¿¡ ºüÁ³À» ¶§ - ¹° ¼Ó¿¡¼­ ¿À·¡ ¹öƼ´Â ¹ý.jpg  (11) À̹ÌÁö rankºÓÀºÇØÀû 06-04 35 6153
885 [°Ç°­]  ´çÀå ¼ú ²÷¾î¾ß ÇÒ À§ÇèÇÑ Áõ»ó 7°¡Áö Á¤¸®!  (1) À̹ÌÁö rankÆ÷ÀÌ¿¡¸¶ 06-04 15 1526
884 [°Ç°­]  ¾È±¸°ÇÁ¶Áõ  À̹ÌÁö rank¹®¼öº¸»ì 06-04 19 1336
883 [°Ç°­]  ÀÕ¸öÀÌ º×°í ¾ÆÇö§ÀÇ ¿øÀΠ (1) À̹ÌÁö rank»î°úÁ×À½ÀÇ°æ°è 06-03 17 1891
882 [°Ç°­]  ¹æ½ÉÇÏ¸é °ñº´µå´Â °ñ´Ù°øÁõ ¿¹¹æÇÏ±â  (1) À̹ÌÁö rank¹®¼öº¸»ì 06-03 14 715
881 [°Ç°­]  ¸ñ ¸Û¿ïÀÌ »ý±â´Â ¿øÀΠ À̹ÌÁö rank»î°úÁ×À½ÀÇ°æ°è 06-02 17 1541
880 [°Ç°­]  °ÅºÏ¸ñ ÀÚ¼¼ ¹Ù¸£°Ô ÇÏ´Â ²ÜÆÁ  (8) À̹ÌÁö rank»Í³¢ 06-02 20 3091
 1  2  3  4  5  6  7  8  9  10  ´ÙÀ½
Á¤º¸ ¿ù°£ Ãßõ  (´õº¸±â)
Á¤º¸ ¿ù°£ Á¶È¸  (´õº¸±â)
Á¤º¸ ¿ù°£ ´ñ±Û  (´õº¸±â)

°øÀ¯Çϱâ

ÀÌÅä·£µå ·Î°í

°èÁ¤ ã±â ȸ¿ø°¡ÀÔ
¼Ò¼È·Î±×ÀÎ